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Abstract
Levodopa has been at the forefront of antiparkinsonian therapy for a half century. Recent advances 
in functional brain imaging have contributed substantially to the understanding of the effects of 
levodopa and other dopaminergic treatment on the activity of abnormal motor and cognitive brain 
circuits in Parkinson’s disease patients. Progress has also been made in understanding the 
functional pathology of dyskinesias, a common side effect of levodopa treatment, at both regional 
and network levels. Here, we review these studies, focusing mainly on the new mechanistic 
insights provided by metabolic brain imaging and network analysis.
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Introduction
The dopamine precursor levodopa has been the most effective medication available for the 
treatment of Parkinson’s disease (PD) in the past 50 years. Because PD is characterized by 
nigrostriatal dopamine deficiency, levodopa administration is expected to reverse the 
functional and neurochemical changes seen in the brains of PD patients. Brain imaging 
studies have largely supported this general mechanism with respect to the treatment of PD 
motor symptoms.1–5 That said, the specific mechanisms underlying the cognitive and motor 
side effects of dopaminergic treatment remain poorly understood, despite the use of 
advanced research imaging tools.
Functional brain imaging techniques, such as positron emission tomography (PET), single 
photon emission computed tomography (SPECT), and functional magnetic resonance 
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imaging (fMRI), have contributed greatly to the study of the effects of levodopa on neural 
activity on the regional and network levels. As a marker of synaptic activity, regional 18F-
fluorodeoxyglucose (FDG) uptake measured with PET has unique advantages in this regard. 
A number of FDG PET studies have examined the metabolic changes induced by levodopa 
treatment. Different analytical strategies have been employed to this end, such as mass 
univariate statistics and multivariate spatial covariance approaches, to examine isolated 
regions and whole brain networks, respectively.
The Abnormal PD State and the Metabolic Effects of Levodopa
When dopaminergic abnormalities were first described in PD,6, 7 the contribution of other 
brain regions to the disease landscape was unknown. With the advent of FDG PET imaging 
in the 1980’s, metabolic abnormalities became evident in the cerebral cortex of PD patients.8 
Subsequently, disease-related abnormalities in regional metabolic activity discerned with 
FDG PET were found to correlate with the loss of presynaptic nigrostriatal dopaminergic 
function measured with 18F-fluorodopa (FDOPA) PET. Both metabolic activity and striatal 
FDOPA uptake correlated with independent motor ratings.9 It has since been understood that 
in PD, dopamine deficiency results in brain-wide abnormalities, which are not restricted to 
the basal ganglia.10–12 Thus, although dopaminergic imaging can be used for the direct 
assessment of presynaptic nigrostriatal terminals, metabolic imaging with FDG PET can be 
used to characterize circuit-level changes in cortico-striato-pallido-thalamo-cortical 
(CSPTC) loops and related pathways in the resting state. In particular, spatial covariance 
analysis of metabolic scans have been invaluable in identifying network abnormalities 
related to PD, and have resulted in the characterization of different patterns representing 
specific disease manifestations: akinesia-rigidity, tremor, and cognitive impairment.13, 14 
One of these patterns, the Parkinson’s disease motor-related pattern (PDRP), is characterized 
by increased pallidothalamic and pontine metabolic activity, associated with covarying 
reductions in premotor, supplementary motor and parietal association regions (Fig. 1A). 
Expression values for this pattern consistently correlate with standardized motor disability 
ratings.13, 15 Nonetheless, PDRP expression has recently been found to be abnormally 
elevated in the ipsilateral hemispheres of early stage patients with hemi-parkinsonism and in 
prodromal subjects with REM sleep behavior disorder (RBD).16–18 Thus, the PDRP is 
sensitive to disease progression in the “premotor period” of PD, which antecedes the clinical 
onset of the actual movement disorder. The metabolic topography of the PDRP accords well 
with predictions based upon the classical “box and line” model of CSPTC motor circuitry.19 
In this vein, a close relationship was found between PDRP expression and spontaneous 
subthalamic nucleus (STN) neuronal firing rates recorded in PD patients undergoing DBS 
surgery.20 Robust relationships also exist between PDRP subject scores and corresponding 
FDOPA PET measures of presynaptic nigrostriatal dopaminergic dysfunction obtained from 
the same individuals. A recent study of 106 PD subjects scanned with both FDG and 
FDOPA PET disclosed highly significant correlations between these measures (C. Eggers, 
personal communication). The magnitude of these correlations (r2~0.20–0.30) was modest, 
however, relative to those between network expression and spontaneous STN cell activity 
(r2~ 0.70). Thus, the human PD data suggest that PDRP expression in a given individual is 
associated more closely with factors regulating basal ganglia output rather than input. 
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Notably, a homologous metabolic covariance pattern closely resembling the human PDRP 
has recently been identified in FDG PET scans from macaques with parkinsonism induced 
by chronic systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration 
(Fig. 1B).21 The development of an abnormal PDRP-like topography in this nonhuman 
primate model certainly relates the pattern to nigrostriatal dopamine loss. Given, though, 
that other neurotransmitter systems are also lesioned in this animal model,22 one cannot 
conclude that the relationships observed between the PDRP network and dopamine are in 
any sense exclusive.
It is not known whether levodopa treatment modulates PDRP activity directly through 
dopaminergic projections to putaminal “front end” regions, or indirectly through functional 
modulation of pallidothalamic inhibitory outflow pathways by way of the STN,23 or through 
a combination of the two effects. It is, however, readily apparent that the abnormal 
elevations in PDRP expression that typify the disorder are reduced by levodopa treatment 
(Fig. 1C).1, 24, 25 Indeed, the degree of network suppression achieved by the drug in 
individual patients correlated with the improvement in motor ratings determined by an 
independent observer.1, 25 This “network normalization” hypothesis is supported by fMRI 
data showing levodopa-mediated reductions in the overactive neural responses seen in PD 
subjects scanned in the baseline (off-medication) condition during the performance of a 
visuomotor task,4 as well as partial restoration of neural functional connectivity during 
motor task performance.5 Nonetheless, other fMRI studies have produced inconsistent 
findings, with increases as well as decreases in motor cortical activation in response to 
levodopa treatment.26, 27 At least some of the differences between these studies can be 
attributed to reversal of the abnormal resting state increases in motor network activity seen 
in PD patients undergoing dopaminergic pharmacotherapy.28 Indeed, by separately 
quantifying network expression at rest and during movement, this H215O PET study 
suggested that the dominant effect of levodopa was to lower the abnormal elevations in 
resting state motor network activity recorded at baseline in unmedicated PD subjects. 
Treatment-mediated changes in the motor activation response (measured, e.g., by the 
movement-rest difference in blood oxygen-level dependent (BOLD) fMRI signal) proved to 
be less robust than corresponding changes in resting state activity. Further research is 
needed to gain a better understanding of the mechanism of levodopa treatment at the 
systems level.
Levodopa Effects on Cognitive Function in Parkinson’s Disease
In addition to ameliorating motor manifestations of PD, levodopa impacts cognitive 
functioning in patients with this disorder. Spatial covariance analysis of FDG PET scans 
from PD patients has revealed a distinct metabolic topography unrelated to the PDRP, 
associated with performance on tests of memory and executive functioning in this 
population (Fig. 2A).29 Expression values for this PD cognition-related metabolic pattern 
(PDCP) have been found to correlate consistently with performance on the California Verbal 
Learning test (CVLT), Trail Making Test B, and the Stroop Tests, as well as other tests 
involving executive functioning, such as the Symbol Digit Monitoring Test (SDMT) and the 
Hooper Visuospatial Orientation Test (HVOT)) (Fig. 2B).15, 30 The PDCP topography is 
characterized by reductions in medial prefrontal, premotor and parietal activity, covarying 
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with relative increases in the cerebellum and brainstem. Increased PDCP expression has 
been associated with advancing cognitive impairment in PD populations, 30 although the 
progression rate for this network is generally slower than that for PDRP expression in the 
same subjects.15, 17 In addition to displaying excellent test-retest reproducibility,29 PDCP 
expression values appear to be relatively insensitive to potentially confounding placebo 
effects.31 Computation of PDCP expression performed on a prospective individual case 
basis have revealed robust correlations between these values and measures of 
neuropsychological performance obtained at the time of imaging.13, 31 Apart from providing 
further substantiation of PDCP expression as an imaging marker of executive dysfunction in 
PD, network analysis has demonstrated that the PDCP topography itself is highly replicable 
across populations (K. L. Leenders, personal communication). Needless to say, the validitiy 
of the PDCP is substantiated by its close topographic relationship with the pattern of cortical 
histopathological changes associated with cognitive impairment seen in PD postmortem 
specimens.32
In contrast to the uniform PDRP responses observed in PD subjects undergoing levodopa 
treatment, concurrent treatment-mediated changes in PDCP expression were substantially 
more varied when measured in the same individuals.29 Interestingly, “cognitive responders” 
(i.e., subjects whose executive dysfunction improved with levodopa administration) 
exhibited concurrent treatment-mediated reductions in PDCP expression that were not seen 
in “cognitive non-responders” (i.e., subjects whose executive deficit did not improve during 
levodopa administration).31 Of note, despite the differences in PDCP modulation that 
distinguished “cognitive responders” from “non-responders” to levodopa, significant 
treatment-mediated reductions in PDRP expression were present in both treatment 
subgroups. These results highlight the functional disparity between the motor and cognitive 
network changes that occur in individual patients during levodopa treatment.3
The data also suggest that the cognitive response to levodopa is influenced by baseline 
PDCP activity.31, 33 That is, higher baseline network expression levels, which signify more 
advanced cognitive impairment in PD patients15, 30 is associated with improved test 
performance during treatment. This supports the inverted U hypothesis of levodopa-learning 
(Fig. 2C).34 PD subjects with greater baseline deficits (and higher baseline PDCP scores) 
also exhibited commensurately higher PDRP expression levels, signifying greater 
involvement of motor as well as cognitive disease networks. Such individuals may possess a 
greater degree of neurodegenerative change in the substantia nigra pars compacta, with 
dopaminergic cell loss extending beyond the ventral midbrain (which projects 
predominantly to the motor-related posterior putamen) into the dorsomedial midbrain 
(which projects to cognition-related caudate and anterior putamen). In support of this 
hypothesis, a recent dual-tracer study revealed a significant negative correlation between 
caudate DAT binding and PDCP expression.33 Similarly, other studies have found 
correlations between degree of cognitive impairment and presynaptic dopaminergic ligand 
binding in both the caudate and putamen.35, 36 Thus, patients with larger baseline deficits in 
caudate dopaminergic innervation are more likely to benefit cognitively from levodopa, with 
greater treatment-mediated PDCP modulation and concomitant improvement in executive 
functioning.31 That said, data from a large cross-sectional PD sample suggest that PDCP 
expression continues to increase monotonically in PD subjects as cognitive impairment 
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progresses and evolves into actual dementia (Fig. 2D).13, 30 It is likely that the substantial 
elevations observed in this context represent the development of inherent neurodegeneration 
involving cortical network regions,32 rather than functional deafferentation effects. 
Cognitive dysfunction in such patients is unlikely to improve with dopaminergic 
pharmacotherapy despite the presence of high baseline PDCP levels.14
Relationship of Metabolic Activity to Dopaminergic Functioning
While many studies have examined either dopaminergic deficits or metabolic abnormalities 
in relation to the motor and cognitive manifestations of PD, only a few have directly 
examined the relationship between cerebral metabolism and nigrostriatal dopaminergic 
integrity.9, 15, 17, 36 While both putaminal FDOPA uptake and PDRP expression correlate 
with parkinsonian bradykinesia and rigidity, gait dysfunction is likely associated with other 
neurotransmitters. Indeed, the risk of falling in PD has been linked to cholinergic 
dysfunction.37 Moreover, both the motor and the non-motor manifestations of the disorder 
have been associated with deficits in more than one neurotransmitter system.38, 39
Some insight into the relationships between nigrostriatal dopaminergic integrity, metabolic 
network expression, and the clinical manifestations of PD has been achieved through dual 
tracer radionuclide imaging. A recent large scale dual tracer PET study (C. Eggers, personal 
communication) rigorously assessed the relationship between loss of nigrostriatal 
dopaminergic terminals (quantified with FDOPA PET) and PDRP/PDCP expression values 
(quantified with FDG PET) in individual PD subjects. As in other studies, modest 
correlations were discerned between these measures. Specifically, PDCP expression 
correlated with caudate FDOPA uptake. By contrast, after adjusting for individual 
differences in PDCP expression, PDRP values were found to correlate with FDOPA uptake 
in the posterior putamen.33 Still, the magnitude of these correlations was weaker than the 
more robust correlations that were previously demonstrated between PDRP activity and 
basal ganglia output as measured by spontaneous STN firing rates in awake, alert PD 
patients.20 These findings suggest that although presynaptic dopamine loss in PD is 
associated with a characteristic set of disease-related metabolic abnormalities at the regional 
and systemic levels, these changes can hardly be viewed as interchangeable. Indeed, the 
network-level abnormalities seen in PD cannot be readily ascribed to functional/anatomical 
changes involving a single neurotransmitter system.
Blood Flow-Cerebral Metabolism Dissociation Induced by Levodopa
Quantitative measurements of metabolic network activity have provided important systems 
level information concerning the action of levodopa and other therapeutic interventions 
resting state cerebral function in PD subjects. Indeed, as observed with levodopa, stereotaxic 
surgical procedures, such as high frequency STN deep brain stimulation (DBS),1, 40 
lesioning (subthalamotomy),41 and subthalamic gene therapy with an adeno-associated virus 
(AAV) borne glutamic acid decarboxylase (GAD) gene.42 have been found to modulate 
PDRP but not PDCP activity in the course of treatment.14 As also seen with levodopa, 
clinical outcomes following treatment correlated with the degree to which abnormal baseline 
PDRP elevations were suppressed (normalized) by the intervention.1, 14 Unexpectedly, 
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though, when the effects of levodopa on PDRP expression were compared in concurrently 
acquired scans of cerebral metabolism (FDG PET) and blood flow (H215O PET) from PD 
subjects, a marked dissociation between the two network response measures was observed at 
the individual patient level.43 In the unmedicated baseline state (12 hours off levodopa), a 
close correlation was present between PDRP expression values computed in scans of 
cerebral metabolic rate (CMR) glucose and cerebral blood flow (CBF) from the same 
individuals.44 Indeed, analogous correlations have been observed between network values 
computed in FDG PET and scans of cerebral perfusion obtained with H215O PET or, non-
invasively, using arterial spin labeling MRI methods.45 While CMR and CBF network 
measures are highly intercorrelated in PD patients scanned off medication, Hirano and 
colleagues found that levodopa treatment resulted in a dissociation between these effects 
(Fig. 3A). Whereas effective PD treatment with STN DBS was found to reduce abnormally 
elevated metabolic network activity in CMR as well as CBF scans,43 levodopa titrated to 
achieve comparable clinical benefit resulted in consistent CBF increases, despite the 
presence of concurrent reductions in network activity in CMR scans acquired in the same 
subjects (Fig. 3B). Interestingly, PD patients experiencing levodopa-induced dyskinesias 
(LIDs) were found to have substantially higher on-state CBF in PDRP regions, than their 
non-dyskinetic counterparts.43 By contrast, however, levodopa-mediated reductions in CMR 
in these areas were of similar magnitude in LID and non-LID subjects. These divergent 
effects suggest that levodopa exerts distinct hemodynamic effects in network regions, apart 
from the correction in abnormally elevated synaptic activity that is concurrently observed in 
the same brain areas.
The mechanism of levodopa-mediated flow-metabolism dissociation was investigated in an 
autoradiographic study of the unilateral 6-hydroxydopamine (6-OHDA) lesioned rat.46 The 
results closely paralleled the human imaging findings: rats acutely and chronically treated 
with levodopa exhibited uncoupling of CBF and CMR in the striatum and globus pallidus 
(GP) and in the primary motor cortex. With chronic treatment, the rats also exhibited 
increase in blood brain barrier (BBB) permeability involving the striatum and substantia 
nigra, as well as an increase in on-state CBF in these regions. In a recent dual tracer (FDG 
and H215O) microPET study conducted in the awake unilateral 6-OHDA rat model,47 there 
was evidence (Fig. 4A) of a significant CBF/CMR dissociation in the ipsilateral striatum 
after treatment with a single levodopa injection. Of note, this treatment-mediated increase in 
local CBF was observed while the animals were under anesthesia (Fig. 4B). It is therefore 
likely that the observed changes are unrelated to concurrent motor manifestations.46, 47 
Moreover, the autoradiography results suggest that the increases in local CBF that 
accompany the induction of LID may be associated with a concurrent BBB breach in the 
same brain regions.46 Studies are in progress using the rat model to examine the specific 
changes in CBF/CMR coupling that take place following chronic levodopa treatment and the 
induction of dyskinesias (see below). Parallel studies are being conducted to assess the 
relationship between levodopa-mediated flow-metabolism dissociation, BBB permeability, 
and the occurrence of LID in human PD subjects.
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Vascular Changes with Chronic Levodopa Treatment: Association with LID
The concept of neurovascular coupling is associated with the phenomenon of functional 
hyperemia, which relates the brain CBF regulation to synaptic activity.48 The cerebral 
vasculature is known to be coordinately controlled by neurovascular mechanisms, which 
ensure that blood delivery matches neuronal energy needs such that under most 
physiological conditions, increases in synaptic activity result in parallel increases in local 
CBF. Nonetheless, uncoupling has been reported in different conditions, in health, disease or 
after pharmacological treatment,43, 49, 50 and molecular studies provide potential 
mechanisms for this phenomenon.51–53 An early study conducted in the unilateral 6-OHDA 
rat model to examine the cellular effects of chronic levodopa treatment52 revealed 
endothelial proliferation and likely angiogenesis involving the striatum and its output 
structures. Indeed, these changes were highlighted by increased staining for nestin (a model 
marker of immature endothelial cells) as well as decreased staining of endothelial barrier 
antigen on the blood vessel wall (a marker of vasculature integrity). A subsequent study 
utilizing the same animal model51 found that chronic levodopa treatment induced expression 
of vascular endothelial growth factor (VEGF) in the basal ganglia in a dose dependent 
fashion. In this model, VEGF was expressed predominantly in astrocytes and astrocytic 
processes near blood vessels. In parallel, the authors used the UK Brain Bank to examine 
postmortem tissue from chronically levodopa treated PD patients. They found increased 
nestin staining and VEGF mRNA expression in the striatum of these specimens.
What could be the significance then of this levodopa-mediated CBF-CMR uncoupling and 
of the vascular changes observed in the brain of animal models and postmortem tissue of PD 
patients? Previously, levodopa-mediated flow-metabolism dissociation was demonstrated in 
chronically treated PD patients. While the phenomenon was identified as a consistent 
response to levodopa administration in PD subjects without LID, flow-metabolism 
dissociation was particularly pronounced in the small number of individuals with this 
complication of treatment.43 Indeed, in that study, the increase in CBF observed with 
levodopa administration correlated with duration of treatment. Moreover, in the rat model, 
endothelial proliferation, likely reflecting underlying angiogenesis, was featured specifically 
in animals with discernible dyskinesias.52 In a subsequent study,51 administration of a 
VEGF signaling inhibitor blocked the appearance of markers of BBB permeability (albumin 
extravasation) and angiogenic response (nestin and VEGF expression) that were seen in 
vehicle-treated rats after chronic levodopa treatment. Furthermore, VEGF inhibition 
significantly attenuated the expression of dyskinesias in LID animals.51
LID is currently thought to relate to pre- and post-synaptic changes that result in 
dopaminergic imbalance.54 Indeed, postsynaptic changes likely play an import role in LID 
development. This point is illustrated in a recent case report55 describing a patient who 
developed LID after chronic treatment of a non-progressive post-traumatic lesion. That said, 
a recent report56 suggests that the development of LID relates to the degree of dopaminergic 
denervation present at baseline in the putamen. This observation, if confirmed, strongly 
implicates presynaptic mechanisms in the development of LID. Independently, in both PD 
patients and rodent models, dyskinesias have been associated with larger increases in striatal 
extracellular DA levels after levodopa administration.57, 58 Entry of levodopa into the brain 
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is regulated by endothelial cells at the blood-brain barrier. Moreover, vascular smooth 
muscle contraction is regulated to a substantial degree by dopamine D1 receptors.59 At 
antiparkinsonian treatment doses, dopamine binding to vasculature receptors is likely to 
result in vasodilation and local blood flow increases.60 This increase in local CBF may not, 
however, be beneficial in the long term. As noted above, chronic levodopa administration 
been shown in the rat model to induce endothelial proliferation and microvasculature 
alterations in dyskinetic animals.
Thus, it is tempting to speculate that chronic levodopa treatment leads to the development of 
microvascular changes such as angiogenesis, which under specific circumstances, can 
enhance the transport of the drug across the BBB. Indeed, the autoradiographic data suggest 
that enhanced BBB permeability, as well as concurrent increases in local CBF, are dopamine 
dependent phenomena that are not present in the off-state. That, in fact, may explain earlier 
observations of intact BBB permeability in parkinsonian non-human primates scanned in the 
absence of medication.61 According to our model, newly formed vessels may be 
supersensitive to dopamine, and the resulting CBF increase following levodopa 
administration, leads to an increase in perfusion pressure, and a treatment state-dependent 
breach of the BBB in brain regions, characterized specifically by increased local dopa 
decarboxylase (DDC) expression and comparatively large numbers of vascular dopamine 
receptors. Recent data from PD subjects receiving levodopa infusions during combined FDG 
and H215O PET scanning confirmed that dopamine-mediated hemodynamic responses were 
elevated in LID vs. non-LID subjects, and that capillary reserve in areas of levodopa-
mediated flow-metabolism dissociation was also increased in the former group. These 
findings are consistent with a recent fMRI study in which putamen activity was elevated in 
LID patients attempting to suppress involuntary movements relative to their non-LID 
counterparts.62 More research is needed to determine whether the degree of flow-
metabolism dissociation seen in PD patients is predictive of the subsequent development of 
LID in these individuals.
Future Directions
Advances in imaging technology, computational methods, and data analysis have led to a 
better understanding of how levodopa acts to improve quality of life for PD patients. The 
use of objective, voxel-based image analysis tools to assess nigrostriatal dopaminergic loss 
in PD subjects, in conjunction with advanced mapping approaches to evaluate the effects of 
these and related neurotransmitter changes on brain function, have provided a rigorous 
means of quantifying disease progression and treatment effects at the systems level. Recent 
work has shown the utility of this multi-modal approach in characterizing the circuit changes 
that underlie cognitive and motor disease manifestations. In particular, the results of network 
analysis have shed light on the mechanism by which levodopa affects cognitive functioning 
in PD patients, as well as the distinct neurovascular changes that underlie the occurrence of 
LID in these individuals. This unique information may help in the development of new 
treatment strategies directed at these major clinical challenges.
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Figure 1. 
Overlays illustrating regional homologies between the abnormal metabolic covariance 
patterns identified in human patients with idiopathic Parkinson’s disease (PD) and monkeys 
with experimental parkinsonism induced by systemic 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) exposure. (A) The abnormal PD motor-related spatial 
covariance pattern (PDRP) identified consistently in multiple independent patient 
cohorts.13, 14 (B) Parkinsonism-related spatial covariance pattern (PRP) identified by the 
analysis of FDG PET scans acquired in MPTP-lesioned and normal macaque monkeys. The 
PRP spatial topography was similar to that of the PDRP; similar metabolic changes were 
observed in homologous brain regions comprising the two covariance patterns. [Both spatial 
covariance patterns were displayed on standard MRI brain templates. Voxels with positive 
loadings (metabolic increases) are color-coded from red to yellow; those with negative 
loadings (relative metabolic reductions) are color-coded from blue to green.] (C) Treatment-
mediated changes in PDRP expression (mean±SE) following stereotactic surgical 
interventions (shaded bars) targeting the subthalamic nucleus (STN): microlesion (n=6),63 
subthalamotomy (n=6),41 and deep brain stimulation (DBS) (n=18).64 Changes in network 
expression during levodopa (LD) administration (n=18)31 (solid bar), as well as the test-
retest variability of this measure (n=14)1 (open bar) are depicted for comparison. Significant 
PDRP modulation was evident following subthalamotomy, STN DBS, and levodopa 
treatment but not microlesion. [**p<0.01, ***p<0.001 for the comparison of changes in 
PDRP expression with each intervention with those observed during test-retest evaluation, 
RMANOVA.] [A, B: Adapted from J Cereb Blood Flow Metab, Y. Ma et al. Abnormal 
metabolic brain networks in a nonhuman primate model of parkinsonism, 2012; 32(4): 633–
642.21 C: Adapted from Ann Neurol, M. Niethammer and D. Eidelberg. Metabolic brain 
networks in translational neurology: concepts and applications, 72(5): 635–647, Copyright 
(2012),14 with permission from John Wiley and Sons.]
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Figure 2. 
(A) Parkinson’s disease cognition-related covariance pattern (PDCP). This covariance 
pattern is characterized by reduced metabolic activity in the dorsal premotor cortex, rostral 
supplementary motor area (preSMA), precuneus, and posterior parietal regions, associated 
with relatively increased activity in the cerebellum.15 [In the representative slices, relative 
metabolic increases are displayed in red; relative metabolic decreases are displayed in blue. 
Slices were overlaid on a standard MRI brain template.] (B) PDCP expression correlates 
with performance on neuropsychological tests of memory and executive functioning in non-
demented PD patients. For the California Verbal Learning Test: Sum 1 to 5 (CVLT sum), 
this correlation was significant for the entire cohort (n=56; r=−0.67, p<0.001), as well as for 
the original group used for pattern derivation (circles; n=15: r=−0.71, p=0.003) and in two 
prospective validation groups (squares; n=25: r=−0.53, p=0.007; triangles; n=16: r=−0.80, 
p<0.001).15 (C) Hypothetical relationship between levodopa-mediated changes in cognitive 
performance, baseline PDCP expression, and caudate dopamine transporter (DAT) binding. 
Based upon published data,31, 33 we propose that an inverted U-shaped relationship exists 
between the changes in cognitive functioning observed during levodopa treatment (y-axis) 
and baseline measurements of caudate dopaminergic input (horizontal bar) and PDCP 
metabolic network activity (x-axis). The numbers at the top of the horizontal bar represent 
Ko et al. Page 14
Mov Disord. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
the caudate DAT binding values that correspond to PDCP scores of 1.0, 2.0, and 3.0, 
respectively. These estimates were based upon the best fitting linear relationship of the two 
measures (mean caudate DAT binding = 0.94–0.15*PDCP score). The area under the curve 
associated with treatment-mediated cognitive benefit (yellow) was defined by an increase in 
individual subject test performance exceeding the independently determined Reliable 
Change Index (RCI)65, 66 on the psychometric outcome measure. For verbal learning 
performance, the RCI cutoff (arrows) was determined to be 0.44, which is hypothesized to 
correspond to PDCP scores between +1.0 and +3.0.31 No cognitive benefit during treatment 
is expected for PDCP values on either side of this interval (gray). (D) Bar graph of PDCP 
expression (mean±SE) in normal subjects, PD subjects without mild cognitive impairment 
(MCI(−)), with single and multiple domain mild cognitive impairment (MCI(s) and 
MCI(m)), and with Parkinson’s disease dementia (PDD). There was a significant difference 
in PDCP expression across the patient and control groups (F(4,70)=8.87, p<0.001; one-way 
ANOVA), and among the PD groups (F(3,56)=4.84; p<0.005), with higher expression in the 
PDD and MCI(m) cohorts compared to the MCI(−) cohort (p<0.03; Tukey-Kramer HSD). 
[For each PD group, PDCP expression was separately compared to healthy control values 
using Student’s t-tests. The asterisks denote significant increases in network activity relative 
to controls (*p<0.05, **p<0.005, ***p<0.0001) in all PD categories including MCI(−).] [A, 
B, D: Reprinted from Trends Neurosci, D. Eidelberg. Metabolic brain networks in 
neurodegenerative disorders: a functional imaging approach, 32(10): 548–557, Copyright 
(2009),13 with permission from Elsevier. C: Reprinted from Neuroimage, M. Niethammer et 
al. Parkinson’s disease cognitive network correlates with caudate dopamine, 78: 204–209, 
Copyright (2013),33 with permission from Elsevier.]
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Figure 3. 
(A) Results of voxel-based searches for brain regions with significant flow-metabolism 
dissociation in response to acute levodopa treatment.43 Top: Treatment-mediated 
dissociation of regional glucose metabolism and cerebral blood flow is present bilaterally in 
the posterior-lateral putamen and adjacent globus pallidus (GP), and in the ventral thalamus. 
Bottom: Significant dissociation effects with levodopa are also present in the dorsal pons and 
midbrain. [Metabolic increases are displayed using a red-yellow scale. Both displays were 
superimposed on a single-subject MRI brain template and thresholded at T=3.28, p=0.001, 
extent threshold >50 voxels (peak voxel, uncorrected).] (B) Bar graph illustrating treatment-
mediated changes (mean±SE) in the expression of the Parkinson’s disease motor-related 
covariance pattern (PDRP) measured in scans of cerebral metabolic rate for glucose (CMR; 
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filled bars) and cerebral blood flow (CBF; open bars) acquired in the same group of PD 
subjects.43 At the network level, a significant dissociation between the CMR and CBF 
treatment responses (p<0.001) is present with levodopa (LD) (left), but not with subthalamic 
nucleus deep brain stimulation (STN DBS) (right). [***p<0.005; **p<0.01; *p<0.05, post-
hoc Bonferonni comparisons of ON vs. OFF values for each treatment group.] [A, B: 
Adapted from J Neurosci, S. Hirano et al. Dissociation of metabolic and neurovascular 
responses to levodopa in the treatment of Parkinson’s disease, 28(16): 4201–4209, 
Copyright (2008),43 with permission from Society for Neuroscience.]
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Figure 4. 
(A) Area of flow-metabolism dissociation in the striatum of the 6-OHDA lesioned rat.47 In 
this unilateral model of nigrostriatal dopaminergic denervation, flow-metabolism 
dissociation was present on the lesioned side following acute levodopa administration. (B) 
Flow-metabolism dissociation in this brain region reflected local CMR reductions taking 
place concurrently with increased CBF during levodopa (LD) treatment. Analogous changes 
were not present in the same area following saline (SAL) administration.
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